Do Not Do Recommendation

 

Levetiracetam is not cost effective at June 2011 unit costs. Offer levetiracetam, oxcarbazepine or sodium valproate (provided the acquisition cost of levetiracetam falls to at least 50% of June 2011 value documented in the National Health Service Drug Tariff for England and Wales) if carbamazepine and lamotrigine are unsuitable or not tolerated.

Do Not Do Recommendation Details

Recommendation:

Levetiracetam is not cost effective at June 2011 unit costs. Offer levetiracetam, oxcarbazepine or sodium valproate (provided the acquisition cost of levetiracetam falls to at least 50% of June 2011 value documented in the National Health Service Drug Tariff for England and Wales) if carbamazepine and lamotrigine are unsuitable or not tolerated.

Interventions:
Levetiracetam

Source guidance details

Guidance:
Epilepsy (CG137)
Published date:
January 2012
Paragraph number:
1.9.3.2
Page number:
26

View all NICE do not do from this Guidance